natgillin/translations-raw huggingface dataset:
The method of claim 7 or 8, wherein each of the fitted relations is a regression model and the weighting factors are, or are based on, regression coefficients from the fitted relations. 
Postupak u skladu s patentnim zahtjevom 7 ili 8, naznačen time, da je svaka od prilagođenih zavisnosti regresijski model i faktori ponderiranja su ili se temelje na regresijskim koeficijentima 1z prilagođenih zavisnosti .
The agent according to claim 5, wherein the agent is for treating intermittent claudication. The agent according to claim 5, wherein the agent is for treating symptoms associated with spinal canal stenosis. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što je sredstvo za liječenje simptoma povezanih sa stenozom kralježničnog kanala.
Similarly, cachets and lozenges are included. 
Slično, takvi su podijeljeni prašci i pastile.
The kit according to claim 14 further comprising instructions for use of the compound in the treatment of cancer, and more preferably a cancer selected from lung cancer, including non-small cell lung cancer and small cell lung cancer, colon cancer, breast cancer, pancreas cancer, sarcoma, ovarian cancer, prostate cancer and gastric cancer. 
Komplet u skladu sa patentnim zahtjevom 14 koji dalje sadrži uputstva za primjenu sjedinjenja u liječenju raka, i poželjnije raka odabranog od raka pluća, uključujući rak pluća nemalih stanica i rak pluća malih stanica, raka debelog crijeva, kolorektalnog raka, raka dojke, raka gušterače, sarkoma, raka jajnika i raka želuca.
Method for making a printing sheet according to any of the preceding claims, wherein during coating preparation and/or application the pH value of the coating formulations comprising waterglass with a weight ratio of SiO2:Na2O in the waterglass above or equal to 3.2 is kept in the range of 10.5 - 11.5 or smaller or equal to 10wherein if at least 50% of the binder part is constituted by waterglass dilution of the coating formulation to below 70%, preferably to at most 65% can be carried out prior to application of the coating and wherein if at least 75% of the binder part is constituted by waterglass dilution of the coating formulation to at most 65% can be carried out prior to application of the coating. 
Postupak za izradu lista papira za ispis prema bilo kojem od prethodnih zahtjeva, naznačen time da tijekom pripreme i/ili primjene premaza pH vrijednost formulacija premaza koje sadrže vodeno staklo sa težinskim omjerom SiO»:Na,O u vodenom staklu većim ili jednakim 3.2 se drži u rasponu od 10,5 - 11.5 ili manjem ili jednakom 10 pri čemu ako je najmanje 50% vezivnog dijela sadržano u otopini vodenog stakla formulacije premaza do ispod 70%, poželjno do najviše 65% može biti provedeno prije primjene premaza, te pri čemu ako je najmanje 75% vezivnog dijela sadržano u otopini vodenog slakla formulacije premaza do najviše 65% može bili provedeno prije primjene premaza.
The pharmaceutical composition according to claim 9, further comprising one or more of the following: the filler corn starch, the lubricant magnesium stearate or sodium stearyl fumarate and the glidant colloidal anhydrous silica. 
Farmaceutski sastav prema zahtjevu 2, naznačen time, da nadalje obuhvaća jedno ili više od sljedećih sredstava: punilo kukuruzni škrob, mazivo magnezijev stearat ili natrijev stearil-fumarat i klizno sredstvo koloidni bezvodni silicijev dioksid.
Ab is an antibody, or an antigen binding fragment thereof, capable of binding to the human IGF-1R, said antibody comprising the three heavy chain CDRs of sequence SEQ ID No. 
Ab jest antitijelo ili njegov fragment vezan na antigen, koji se može vezati na humani IGF-IR, rečeno antitijelo sadrži tri teška lanca CDRs sekvencije SEQ ID br.
Pharmaceutical composition according to claim 16, wherein the degenerative condition is selected from glaucoma, age-related macular degeneration, uveitis, neuropathic pain, multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease and Alzheimer's disease. 
Farmaceutski pripravak za uporabu kod liječenja upalnih procesa i degenerativnih stanja prema zahtjevu 16, naznačen time da je degenerativno stanje odabrano od glaukoma, makularne degeneracije povezane sa starenjem, uveitisa, neuropatske boli, multiple skleroze, amiotrofične lateralne skleroze, Parkinsonove bolesti i Alzheimerove bolesti.
Ring A is unsubstituted or is substituted with ethyl; or a pharmaceutical acceptable salt, solvate or hydrate thereof. 
KE Ni gdje Prsten A je nesupstituiran ili je supstituiran sa etil; ili na njihove farmaceutski prihvatljive soli, solvate ili hidrate.
The unbound and eluted fractions were collected and analysed by ELISA and SDS-PAGE. 
Vezane i eluirane frakcije su sakupljene 1 analizirane testovima ELISA i SDS-PAGE.
converting the product of step (b) to 
(c) prevođenju produkta iz koraka (b) u
A composition comprising a pharmaceutically acceptable carrier and a modified FGF-21 polypeptide, wherein: 
Smjesa koja sadrži FGF-21 polipeptid prema zahtjevu 19 i farmaceutski prihvatljivi nosač.
generating, with the camera, an electronic image of at least a portion of the form; 
generiranja pomoću kamere, elektroničke slike barem dijela obrasca;
The materials of the plates which are fixedly and two-dimensionally joined to each other also play a part, of course. 
Naravno, također imaju ulogu i materijali ploča koje su čvrsto i dvodimenzionalno spojene jedna s drugom.
The panel as claimed in claim 5, wherein those portions of two material strips (2, 2', 2",...) which extend between respectively two neighboring core elements (1, 1', 1 ",...) are overlapped by a connecting strip located between these core elements (1, 1', 1 ",...). 
Ploča u skladu s patentnim zahtjevom 5, naznačena time što je svaki od predjela dvaju traka od materijala (2, 2 ́, 2 ̋, …), koji predjeli se prostiru između svakog od dva susjedna središnja elementa (1, 1 ́, 1 ̋, …), prekriven jednom trakom za povezivanje, koja leži između tih središnjih elemenata (1, 1 ́, 1 ̋, …).
The compound of claim 17 or 18, wherein R6 is a phenyl group that is optionally substituted by 1 to 5 substituents selected from group B. 
Spoj u skladu s patentnim zahtjevom 17 ili 18, naznačen time što je R6 fenilna skupina izborno supstituirana s 1 do 5 supstituenta, koje se bira iz skupine B.
In particular, an antibody of the present invention can be of IgG 2B class, and can comprise an amino acid sequence set forth in SEQ ID NO: 49, or a variant thereof, as defined supra. 
Antitijelo prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu je navedeno antitijelo IgG 2B klase, i/ili gdje navedeno antitijelo sadrži aminokiselinsku sekvencu predstavljenu u SEQ ID NO: 49.
The long side 7 of the top side of the lamellas 3 and 4, or in other words the free edge thereof, extends practically radially onto the support 2, whereas the short side 6 is situated in a tangent plane on the circumference of the lamellas. 
Duga strana 7 gornje strane lamela 3 i 4, ili drugim riječima njihov slobodni rub, pruža se praktički radijalno na nosač 2, dok je kratka strana 6 postavljana u tangencijalnoj ravnini na obod lamela.
Additive composition for concrete or other cement based materials comprising C-S-H seeds according to claim 11. Use of the C-S-H seeds obtained by the process according to any one of claims 1 to 10, or of the additive composition of claim 12 as hardening accelerator and seeding additive for concrete or other cement based materials. 
Upotreba mulja koji sadrži C-S-H sjeme dobiveno postupkom u skladu s bilo kojim od patentnih zahtjeva 1 do 4, ili praha koji sadrži C-S-H sjeme u skladu s patentnim zahtjevom 7, naznačena time što su mulj ili prah ubrzivači stvdnjavanja i aditivi za zasijavanje betona ili drugih materijala na bazi cementa.
A method of treating a disease related to abnormal activities of JAK3 and/or JAK1 kinases in a human patient, comprising administering the human patient the pharmaceutical composition according to claim 15, wherein the disease related to abnormal activities of JAK3 and/or JAK1 kinases is selected from the group consisting of rheumatoid arthritis, psoriasis, systemic lupus erythematosus, multiple sclerosis, type I diabetes, leukaemia, and lymphoma. 
Korištenje farmaceutskog sastava prema zahtjevu 11 u pripremi lijeka za liječenje ili prevenciju autoimunih bolesti, upalnih bolesti, rakova, mijeloproliferativnih bolesti, bolesti resorpcije kosti, bolesti presatka protiv primatelja, reumatoidnog artritisa, psorijaze, Crohnove bolesti, sistemskog eritemskog lupusa, multiple skleroze, tip I dijabetesa, alergijskih bolesti, kronične opstruktivne plućne bolesti, astme, leukemije 1 limfoma.
The following are aspects of the disclosure: An antibody or antigen-binding fragment thereof, which specifically binds human interleukin-6 receptor (hIL-6R) with a KD of about 500 pM or less, and 300 pM or less, as measured by surface plasmon resonance. 
Antitijelo ili njegov fragment koji se vože na antigen, koji se specifično veže na humani interleukin-6 receptor (hIL6R) s konstantom Kp od 500 pM ili manjom izmjereno površinskom plazmonskom rezonancijom, naznačeno time, da CDR teškog lanca i CDR lakog lanca sadržavaju:
a container that contains a water body; a chemical application system for dosing a flocculant into the water, wherein the chemical application system applies a flocculant to the water in the water body to maintain turbidity of the water below 2 NTU; 
primjenu učinkovite količine flokulanta na vodu u vodenom tijelu radi zadržavanja zamućenosti vode ispod 2 NTU, pri čemu flokulant flokulira suspendirane čvrste u vodi u čestice koje se talože na dno vodenog tijela.
The method of claim 2, characterised by the step of providing quality control for the pharmaceutical product while said plurality of carrier substrates continues to move in said direction. 
Postupak u skladu s patentnim zahtjevom 1, 2 ili 3, naznačen time što se provodi korak kontroliranja kvalitete farmaceutskog proizvoda dok se navedenih više nosivih supstrata (1000) stalno pomiču u navedenom smjeru.
Printing sheet according to any of the preceding claims, characterised in that the binder part comprises a binder or a mixture of binders selected from the group consisting of latex, in particular styrene-butadiene, styrene-butadiene-acrylonitrile, styrene-acrylic, in particular styrene-n-butyl acrylic copolymers, styrene-butadiene-acrylic latexes, acrylate vinylacetate copolymers, starch, polyacrylate salt, polyvinyl alcohol, soy, casein, carboxymethyl cellulose, hydroxymethyl cellulose and copolymers as well as mixtures thereof, preferably provided as an anionic colloidal dispersion in the production. 
Upotreba arka za tiskanje prema bilo kojem od prethodnih zahtjeva, naznačena time da vezivni dio sadrži vezivnu tvar ili mješavinu vezivnih tvari odabranih iz skupine koja se sastoji od lateksa, posebice stiren-butadiena, stiren-butadien-akrilonitrila, stiren-akrila, posebice od stiren-n-butil akrilnih kopolimera, stiren-butadien-akrilnih lateksa, akrilat vinilacetatnih kopolimera, škroba, poliakrilatne soli, polivinil alkohola, soje, kazeina, karboksimetil celuloze, hidroksimetil celuloze i kopolimera kao i njihovih mješavina, poželjno po mogućnosti kao anionska koloidna disperzija u proizvodnji.
The method according to claim 30, wherein the dryer hood is provided drying energy at a rate of less than 3 MMBtu/ton for a duration of at least 60 minutes during the production interval. 
Metoda u skladu s patentnim zahtjevom 3, pri čemu je pokrov sušila (88) opskrbljen energijom za sušenje brzine manje od 3 MMBtu/tona (3165 MJ/tona) u trajanju od najmanje 60 minuta za vrijeme proizvodnog intervala.
A compound of the Formula I: 
Spoj s formulom I: naznačen time da:
A preferred cleavage reaction is the treatment of a quinazoline derivative of the Formula I with pyridine hydrochloride. 
Poželjna reakcija jest obrada derivata kinazolina prikazanog Formulom I sa piridin-hidrokloridom.
The LTE network of claim 6, wherein the SGW is configured to send the special data packet to the source eNB after the SGW performs a path switching, wherein the special data packet is generated by the SGW; and the source eNB is configured to forward the special data packet to the target eNB upon receiving the special data packet sent by the SGW. 
LTE mreža prema zahtjevu 5, naznačena time da je SGW konfiguriran da generira poseban paket podataka i šalje poseban paket podataka prema izvorišnom eNB nakon što SGW provede komutaciju puta; i izvorišni eNB je konfiguriran da prosljeđuje poseban paket podataka prema ciljnom eNB nakon prijema posebnog paketa podataka poslanog od SGW.
Novel compounds and compositions and methods of use 
NOVI SPOJEVI I PRIPRAVCI, TE POSTUPCI NJIHOVE PRIMJENE
An adjusting screw (24) is screwed into the threaded hole (23) of the shank. The adjusting screw (24) has a head (25) with polygonal, preferably hexagonal section. 
Podesivi vijak (24) zavijen u otvor s navojem (23) držača za kontrolu tlaka plina, a navedeni podesivi vijak sadrži vrh (25) -
Long pentraxin PTX3 according to claim 1, which is of natural human or nonhuman, or recombinant origin. 
Dugi pentraksin PTX3 prema zahtjevu 1 ili 2, koji je prirodnog humanog ili nehumanog ili rekombinantnog porijekla.
The aqueous pharmaceutical composition as claimed in any preceding claim, wherein the composition comprises the histidine buffer system at a concentration of 2 to 50 mM. 
Vodeni farmaceutski pripravak sukladno bilo kojem prethodnom patentnom zahtjevu, naznačen time, da pripravak sadrži histidinsko pufersko sredstvo (ili histidinski puferski sustav) u koncentraciji od 2 do 50 mM.
Process for producing ethanol from xylose or a glucose-xylose mixture using a yeast, preferably Saccharomyces cerevisiae, which expresses the protein of claim 1 or 2. Process for producing a fermentation product selected from the group of lactic acid, acetic acid, succinic acid, amino acids, 1, 3-propane-diol, ethylene, glycerol, ß-lactam antibiotics, cephalosporins, biofuels, butanol, ethanol, lactic acid, itaconic acid, preferably butanol, most preferably ethanol whereby the process comprises the steps of: 
Postupak za proizvodnju fermentirajućeg proizvoda odabranog iz grupe mliječne kiseline, octene kiseline, sukcinske (jantarne) kiseline, amino kiselina, 1, 3-propan-diola, etilena, glicerola, B-laktam antibiotika, cefalosporina, biogoriva, butanola, etanola, mliječne kiseline, itakonične kiseline, poželjno butanola, a najbolje etanola naznačen time da postupak sadrži sljedeće korake: a) fermentiranje medija koji sadrži izvor ksiloze s stanicom kvasca kako je definiran u bilo kojem od zahtjeva od 1 do 9, i po želji; b) očuvanje proizvoda fermentacije
The method of claim 1, wherein the anti-a-synuclein antibody or a-synuclein binding fragment is selected from the group consisting of an Fab, an Fab′, an F(ab′)2, an Fd, an Fv, a single-chain Fv (scFv), a single-chain antibody, and a disulfide-linked Fv (sdFv). 
Protutijelo, ili njegov antigenski vežući fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačeno time što protutijelo, ili njegov antigenski vežući fragment, je konjugirano sa sredstvom kojeg se bira iz skupine koju čine terapijsko sredstvo, predlijek, peptid, protein, enzim, virus, lipid, biološki odgovor modifikator, farmaceutsko sredstvo, te polietilen-glikol (PEG).
reducing the amount of 14-hydroxycodeinone in the oxycodone hydrochloride composition formed in step (iii) to produce an oxycodone hydrochloride composition having less than 25 ppm 14-hydroxycodeinone. 
Postupak prema zahtjevu 1, naznačen time da rezultantni sastav oksikodon hidroklorida sadrži 14-hidroksikodeinon u količini manjoj od 10 ppm.
The method of claim 1, wherein the dosing regimen results in a plasma buprenorphine profile wherein the mean plasma buprenorphine concentration after administration of the third transdermal patch is about 800 pg/ml. 
Korištenje iz zahtjeva 3, naznačeno time da režim doziranja dovodi do profila buprenorfina u plazmi kod kojega srednja koncentracija buprenorfina u plazmi nakon davanja trećeg oblika doziranja iznosi približno $00 pg/ml.
The compound as defined in any one of claims 1 to 11 for use in a method of treating psychotic, neurological and cognitive functions diseases and disorders in a mammal, comprising administration to a subject in need therefor of a therapeutically effective amount of the compound as defined in any one of claims 1 to 11. 
Spoj kako je definiran u bilo kojem zahtjevu 1 do 11, naznačen time da se koristi u metodi liječenja psihotičkih, neuroloških bolesti ili poremećaja 1 bolesti ili poremećaja kognitivnih funkcionalnosti kod sisavaca, pri čemu navedena metoda podrazumijeva administraciju osobama u potrebi terapeutski učinkovite količine spoja kako je definiran u bilo kojem od zahtjeva 1 do 11.
The weight of the ascorbate component may be 20 to 85 g, for example 25 to 75 g, for example 20 to 60 g, for example 50 to 60 g. In an embodiment, the ascorbate component comprises (or consists essentially of) sodium ascorbate and ascorbic acid. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što pripravak sadrži 20 do 85 g askorbata kao komponente, primjerice 25 do 75 g, primjerice 20 do 60 g, primjerice 50 do 60 g.
Method according to claim 6, 7 or 8, wherein the metal cation is a monovalent metal cation, more in particular K or Na. 
Postupak prema zahtjevu 6, 7 ili 8, pri čemu je kation metala monovalentni kation metala, još poželjnije K ili Na.
is selected from the group consisting of pyridyl, pyrimidinyl, quinolyl, isoquinolyl, quinazolyl, quinoxalinyl, napthyridinyl, pthalazinyl, azabenzofuryl and azaindolyl, each of which may be optionally substituted with from one to two methyl, -amino, —NHMe, —NMe2, methoxy, hydroxymethyl or halogen groups. In another preferred embodiment: —W— is selected from the group consisting of 
Ri, R5, Ri", R5, R5 i Ri" gu nezavisno jedan od drugog H ili metil, uz uvjet da je najviše jedan metil; i R' se izabire iz skupine koja obuhvaća piridinil, pirimidinil, kinolil, izokinolil, kinazolil, kinoksalinil, naftiridinil, ftalazinil, azabenzofuril i azaindolil, od kojih svaki može po izboru biti supstituiran jednim do dva supstituenta izabrana iz skupine koja obuhvaća metil, -amino, -NHMe, -NMe,, metoksi, hidroksimetil i halogen,
The compound for use of any one of claims 1-11, wherein the method comprises the administration of said compound as a capsule or as a tablet. The compound for use of claim 12, wherein the method comprises the administration of said compound in 10 mg or 25 mg of a capsule. 
Tvar za uporabu u skladu s patentnim zahtjevom 15, pri čemu navedena metoda obuhvaća oralnu primjenu navedene tvari, poželjno u kapsuli ili tableti; pri čemu navedena metoda poželjno obuhvaća davanje tvari u kapsulama od 10 mg ili 25 mg.
A compound of formula (X): or a salt thereof. 
Spoj naznačen time da ima formulu (X): o Ga HN
OBJECTS AND SUMMARY OF THE INVENTION It is therefore an object of the present invention to avoid at least one of the above mentioned disadvantages and to provide the initially mentioned dental post with good optical properties, in particular to provide good light conduction properties and light emission over a comparatively large surface area of the post, by keeping restrictions on the choice of the resin material as low as possible. 
Zubni potporanj u skladu s najmanje jednim od patentnih zahtjeva 1 do 7, naznačen time što je u najmanju ruku dio navedenih vlakana (8) predviđen za provođenje svjetla kroz navedeni potporanj, gdje su krajevi navedenih svjetlovodnih vlakana (8) na stražnjem kraju (3) navedenog potpornja pripremljeni kao površina za ulaz svjetla.
as the annular zone (4) fills up, the flexible detachable tube (7) is pulled up from the annular zone (4) using the external winder (10), in such a way that a constant distance is maintained with respect to the surface of the bed which is building up progressively, said distance always being comprised between 50 cm and 100 cm, 
- dok se prstenasta zona (4) ispunjava odvojiva savitljiva cijev (7) se podiže iz prstenaste zone (4) pomoću vanjskog namotaja (10), na takav način da se održava konstantni razmak u odnosu na površinu sloja koji postupno nastaje, navedeni razmak je uvijek između 50 cm i 100 cm,
The use of a compound or a pharmaceutically acceptable salt thereof as defined in any of claims 1 to 2 in the manufacture of a medicament for the treatment of alcohol related disorders. 
Upotreba spoja, ili njegove farmaceutski prihvatljive soli, u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačena time što je navedeni spoj namijenjen proizvodnji međikamenta za liječenje poremećaja povezanih s alkoholom.
Preparation of the Sample Solutions: 
Datum objave europskog patenta:
In the section above the expression “inert solvent” refers to a solvent which does not react with the starting materials, reagents, intermediates or products in a manner which adversely affects the yield of the desired product. 
U gornjem djelu izraz "inertno otapalo" se odnosi na otapalo koje ne reagira sa polaznim materijalima, reagensima i intermedijerima produkata na način koji štetno utječe na prinos željenog produkta.
additionally contains a buffer; and/or 
(i) < dodatno sadrži pufer; i/ili
Preferably, each side of the first and/or second outer part is decorated, so that decorations appear on both the inner and outer side of the packaging. 
Poželjno je da je dekorirana svaka strana prvog i/ili drugog vanjskog dijela, tako da se dekoracije pojavljuju i na unutarnjoj i na vanjskoj strani pakiranja.
the antibody or fragment thereof comprises a LCVR sequence of SEQ ID NO:28 or SEQ ID NO:118. The use according to claim 5 or 6, wherein the antibody or fragment thereof comprises a HCVR/LCVR combination of SEQ ID NO:20/28 or 116/118. 
Primjena prema zahtjevu 8, naznačena time, što se antitijelo ili njegov fragment sastoji od (a) HCVR sekvence od SEQ ID NO: 20 ili 116 1 LCVR sekvence od SEQ ID NO:28 ili 118, ili (b) HCVR/LCVR kombinacije od SEQ ID NO: 20/28 ili 116/118.
In some embodiments, compounds of the present invention are R. In some embodiments, compounds of the present are S. In some embodiments, compounds of the present invention are racemic mixtures. 
U nekim oblicima, spojevi prikazanog izuma su R. U nekim oblicima, pojevi prikazanog izuma su racemične smjese.
applying hydrostatic pressure in the range of 10 to 100 MPa to said biological material; 
(a) primjenu hidrstatskog tlaka u rasponu od 10 do 100 MPa na navedeni biološki materijal;
The present invention concerns a method for the manufacture of wood fiber or mineral fiber based decorative substrates (1), comprising the steps of: 
PATENTNI ZAHTJEVI nana Postupak za proizvodnju dekorativnih podloga na bazi drvenih vlakana ili mineralnih vlakana, naznačen time što obuhvaća korake:
The anti-CLD18A2 antibody of claim 1, wherein the anti-CLD18A2 antibody comprises a heavy chain constant region having an amino acid sequence represented by SEQ ID NO: 150 and a light chain constant region having an amino acid sequence represented by SEQ ID NO: 41. 
sekvence nukleinske kiseline koja kodira polipeptid koji sadrži varijabilno područje teškog lanca koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 134 i varijabilno područje lakog lanca koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 140;
The peptide according to Claim 3, wherein said fusion protein comprises the N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii). 
Peptid u skladu s patentnim zahtjevom 3, pri čemu navedeni fuzionirani protein sadrži N-terminalne aminokiseline HLA-DR invarijantnog lanca vezanog za antigene (Ii).
In the beverage dispensing assembly of the present invention the cover extends vertically from the substantially flat base part over the collapsible container, contrary to prior art dispensing assemblies in which a pressure chamber is provided in a box-shaped housing with a lid. 
U sklopu za točenje pića prema predloženom izumu pokrov se proteže okomito iz uglavnom ravnog osnovnog dijela preko sklopivog spremnika, suprotno sklopovima za točenje iz stanja tehnike, u kojima je tlačna komora predviđena u kućištu oblika kutije s poklopcem.